Table 3.
25OHD serum levels (ng/ml) in GCT main group and controls
| n | Min | Q1 | Median | Q3 | Max | Mean | SD | |
|---|---|---|---|---|---|---|---|---|
| GCT main group | 165 | 3.4 | 10.50 | 15.80 | 24.40 | 142 | 19.63 | 15.56 |
| Cohort 2 | 84 | 3.1 | 10.50 | 19.15 | 25.90 | 85.1 | 21.27 | 14.54 |
| Cohort 3 | 237 | 3.4 | 11.00 | 18.90 | 26.50 | 148.1 | 22.30 | 17.38 |
median median 25OHD serum levels, mean: mean 25OHD serum level values, Q1 first quartile, Q3 third quartile, SD standard deviation
cohort 2 denotes control group consisting of patients with non-neoplastic scrotal diseases; cohort 3 denotes control group 2 consisting of male urologic patients with non-testicular and non-neoplastic diseases
P = 0.1797 Kruskal Wallis Test for over-all comparison of GCT main group with the two other cohorts